Fenbendazole as an Anticancer Agent: Insights from a Case Series
Published: Feb 13, 2026
4 min. read
Table of Contents
Fenbendazole (FBZ) is an inexpensive, widely available antiparasitic drug primarily used in veterinary medicine. Recent research has investigated its potential as a repurposed anticancer agent. The study conducted by Makis, Baghli, and Martinez (PMC12215191) documents a case series of three patients with advanced cancer who self-administered FBZ, providing preliminary insights into its possible therapeutic effects.
Background and Research Context
According to the study, Fenbendazole belongs to the benzimidazole class of drugs, traditionally used to treat parasitic infections in animals. Preclinical studies indicate that benzimidazoles, including FBZ, may exert anticancer effects through several mechanisms:
- Disrupting microtubule polymerization
- Inducing apoptosis (programmed cell death)
- Arresting the cell cycle at the G2/M phase
- Inhibiting angiogenesis
- Interfering with cancer cell glucose and possibly glutamine metabolism
Despite promising laboratory and animal results, clinical evidence for FBZ in human cancer treatment remains limited (Makis et al., PMC12215191).
Summary of the Case Series
The PMC study reports three cases of advanced-stage cancer patients:
Case 1: Stage IV Breast Cancer
- Patient: 83-year-old female
- Treatment: Self-administered FBZ (222 mg/day) alongside fulvestrant injections and targeted radiation.
- Outcome: Complete remission achieved; follow-up PET scans confirmed no abnormal metabolic activity. The patient remains recurrence-free nearly three years later.
- Observation: FBZ was well tolerated with no reported adverse effects during the treatment period (Makis et al., PMC12215191).
Case 2: Stage IV Prostate Cancer
- Patient: 75-year-old male
- Treatment: FBZ (222–444 mg/day) combined with androgen deprivation therapy (ADT) and supplements.
- Outcome: Near-complete remission; PSA levels remained undetectable over 26 months.
- Observation: No side effects attributable to FBZ were reported (Makis et al., PMC12215191).
Case 3: Stage IIIC Melanoma
- Patient: 63-year-old male
- Treatment: FBZ (222 mg/day) alongside surgery and supplements, with two doses of immunotherapy.
- Outcome: Complete remission observed within weeks; patient remains disease-free for 11 months post-treatment.
- Observation: No adverse effects reported (Makis et al., PMC12215191).
Mechanisms Highlighted in Research
The study emphasizes multiple potential anticancer mechanisms for FBZ:
- Microtubule Destabilization: Similar to vinca alkaloids, FBZ disrupts microtubule formation, inducing mitotic arrest and apoptosis.
- Metabolic Interference: FBZ may inhibit glucose metabolism and other cellular pathways critical for cancer cell survival.
- Apoptosis Activation: FBZ induces cell death via mitochondrial damage and p53 activation.
- Cancer Stem Cell Targeting: Benzimidazoles, including FBZ, may affect cancer stem cells, offering potential long-term antitumor effects (Makis et al., PMC12215191).
Safety and Tolerability Observations
- FBZ was generally well tolerated in all three cases.
- No significant liver toxicity or other serious adverse effects were reported.
- Patients self-administered FBZ without medical prescription, underscoring the importance of controlled clinical studies to validate safety and efficacy (Makis et al., PMC12215191).
Limitations Noted in the Study
The authors caution that:
- The series is small and observational, limiting generalizability.
- Concurrent therapies make it difficult to isolate FBZ’s direct effect.
- Self-medication raises potential risks due to lack of dosage control and monitoring.
- Only rigorous clinical trials can confirm efficacy and safety (Makis et al., PMC12215191).
Conclusion from Research
The PMC case series highlights FBZ as a promising candidate for repurposing in oncology, with observed tumor regression and remission in advanced cancer patients. While preliminary, these findings justify further clinical trials to investigate FBZ’s potential as a safe and effective adjunct or standalone therapy in cancer treatment.
Important Note: Fenbendazole is not approved for human use outside clinical studies. Self-administration carries risks, and these findings do not replace standard cancer care.
